Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received an average recommendation of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $71.40.

A number of equities analysts have commented on the stock. Leerink Partners started coverage on shares of Arcturus Therapeutics in a research report on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target on the stock. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th.

Insider Activity

In related news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This trade represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Franklin Resources Inc. raised its stake in shares of Arcturus Therapeutics by 54.6% during the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after buying an additional 36,714 shares during the last quarter. Geode Capital Management LLC grew its holdings in Arcturus Therapeutics by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock worth $12,810,000 after acquiring an additional 5,789 shares during the period. XTX Topco Ltd raised its position in shares of Arcturus Therapeutics by 51.1% during the 3rd quarter. XTX Topco Ltd now owns 36,990 shares of the biotechnology company’s stock valued at $859,000 after acquiring an additional 12,509 shares during the last quarter. PDT Partners LLC acquired a new position in shares of Arcturus Therapeutics in the 3rd quarter valued at $1,744,000. Finally, Verition Fund Management LLC acquired a new position in shares of Arcturus Therapeutics in the 3rd quarter valued at $420,000. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Trading Up 4.7 %

ARCT stock opened at $18.34 on Friday. Arcturus Therapeutics has a 1-year low of $14.93 and a 1-year high of $45.00. The business’s 50 day moving average is $19.91 and its 200-day moving average is $23.28. The firm has a market cap of $496.78 million, a P/E ratio of -8.26 and a beta of 2.64.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. During the same period last year, the business earned ($0.61) earnings per share. Sell-side analysts forecast that Arcturus Therapeutics will post -2.31 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.